Brookdale Senior Living (BKD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
The annual meeting is scheduled for June 22, 2026, at the principal executive offices in Brentwood, Tennessee, with a record date of April 24, 2026.
Key 2025 initiatives included executive transitions and a new regional operating structure to enhance operational excellence and long-term growth.
The Board expresses confidence in future opportunities and encourages all shareholders to vote.
Voting matters and shareholder proposals
Shareholders will vote on electing nine directors for one-year terms, an advisory say-on-pay vote, and ratification of Ernst & Young LLP as the independent auditor for 2026.
The Board unanimously recommends voting FOR all proposals.
Proxy access and majority voting standards are in place for director elections.
Board of directors and corporate governance
The Board consists of nine directors, with eight incumbents and one new nominee, C. Christian Winkle, replacing a retiring director.
89% of directors are independent, with an average tenure of 3.6 years and diverse expertise in healthcare, finance, hospitality, and real estate.
The Board is declassified, with annual elections, and has adopted robust governance guidelines, including limits on outside board service and meaningful stock ownership requirements.
Board leadership is separated, with an independent Chairman and a CEO.
Four standing committees: Audit, Compensation, Investment, and Nominating and Corporate Governance.
Latest events from Brookdale Senior Living
- Director elections, executive pay, and auditor ratification headline the annual meeting agenda.BKD
Proxy filing30 Apr 2026 - Record 2025 EBITDA and occupancy growth set the stage for robust 2026 performance.BKD
Q4 202510 Apr 2026 - Operational focus, targeted CapEx, and market-driven M&A support growth amid strong demand.BKD
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Q2 saw 20% Adjusted EBITDA growth, higher occupancy, but a wider net loss on higher costs.BKD
Q2 20241 Feb 2026 - 2026 targets $502–$516M Adjusted EBITDA and 8–9% RevPAR growth, led by operational transformation.BKD
Investor Day 202630 Jan 2026 - Q3 2024 delivered 15% EBITDA growth, higher occupancy, and $610M in acquisitions pending.BKD
Q3 202415 Jan 2026 - Strategic acquisitions, strong occupancy, and HealthPlus expansion drive positive 2025 outlook.BKD
Stephens 26th Annual Investment Conference | NASH202413 Jan 2026 - Accelerating occupancy, strong cash flow, and innovation position for sustained growth.BKD
Barclays 27th Annual Global Healthcare Conference26 Dec 2025 - 2024 results beat guidance; 2025 targets 11%-15% EBITDA growth and positive cash flow.BKD
Q4 202415 Dec 2025